1. Home
  2. ATNF vs TOVX Comparison

ATNF vs TOVX Comparison

Compare ATNF & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNF
  • TOVX
  • Stock Information
  • Founded
  • ATNF 2016
  • TOVX 2001
  • Country
  • ATNF United States
  • TOVX United States
  • Employees
  • ATNF N/A
  • TOVX N/A
  • Industry
  • ATNF Biotechnology: Pharmaceutical Preparations
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATNF Health Care
  • TOVX Health Care
  • Exchange
  • ATNF Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • ATNF 4.1M
  • TOVX 4.7M
  • IPO Year
  • ATNF N/A
  • TOVX 2006
  • Fundamental
  • Price
  • ATNF $0.86
  • TOVX $1.16
  • Analyst Decision
  • ATNF
  • TOVX Strong Buy
  • Analyst Count
  • ATNF 0
  • TOVX 1
  • Target Price
  • ATNF N/A
  • TOVX $6.00
  • AVG Volume (30 Days)
  • ATNF 35.6K
  • TOVX 23.1K
  • Earning Date
  • ATNF 05-14-2025
  • TOVX 05-06-2025
  • Dividend Yield
  • ATNF N/A
  • TOVX N/A
  • EPS Growth
  • ATNF N/A
  • TOVX N/A
  • EPS
  • ATNF N/A
  • TOVX N/A
  • Revenue
  • ATNF N/A
  • TOVX N/A
  • Revenue This Year
  • ATNF N/A
  • TOVX N/A
  • Revenue Next Year
  • ATNF N/A
  • TOVX N/A
  • P/E Ratio
  • ATNF N/A
  • TOVX N/A
  • Revenue Growth
  • ATNF N/A
  • TOVX N/A
  • 52 Week Low
  • ATNF $0.90
  • TOVX $1.03
  • 52 Week High
  • ATNF $17.75
  • TOVX $12.25
  • Technical
  • Relative Strength Index (RSI)
  • ATNF 36.88
  • TOVX 44.04
  • Support Level
  • ATNF $0.90
  • TOVX $1.08
  • Resistance Level
  • ATNF $1.02
  • TOVX $1.21
  • Average True Range (ATR)
  • ATNF 0.07
  • TOVX 0.07
  • MACD
  • ATNF 0.00
  • TOVX 0.00
  • Stochastic Oscillator
  • ATNF 37.01
  • TOVX 55.56

About ATNF 180 Life Sciences Corp.

180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: